University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
James L. Rubenstein, MD, PhD

James L. Rubenstein, MD, PhD

Professor in Residence, Department of Medicine, UCSF

Cancer Center Program Memberships

Hematopoietic Malignancies

Education

Stanford University, B.S., June 1985, Biological Sciences
The Rockefeller University, Ph.D., June 1991, Molecular and Cellular Neuroscience (Medical Scientist Training Program)
Cornell University Medical College, M.D., May 1992, Medicine
Stanford University Medical Center, Stanford, CA, Internship/Residency, 1992-1995, Internal Medicine
University of California, San Francisco, San Francisco, CA, Fellowship, 1992-1998, Hematology/Oncology and Neuro-Oncology


Professional Experience

  • 1998-2006
    Assistant Adjunct Professor of Medicine, Attending Physician in Hematology/Oncology, University of California, San Francisco
  • 2006-2009
    Assistant Professor of Medicine in Residence, University of California, San Francisco
  • 2009-2013
    Associate Professor of Medicine in Residence, University of California, San Francisco
  • 2013-present
    Professor in Residence, Department of Medicine, University of California, San Francisco

Honors & Awards

  • 1985
    Phi Beta Kappa
  • 1985
    Departmental Honors in Biological Sciences
  • 1985
    Honors in Humanities
  • 1995
    Housestaff Research Award
  • 1998
    Young Investigator Award -American Society of Clinical Oncology
  • 1999
    American Brain Tumor Association Fellowship
  • 2000
    UCSF/Mt Zion Clinical Investigator Research Program
  • 2000
    California Cancer Research Program Clinical Scientist Development Award
  • 2001
    UCSF/Mt Zion Clinical Investigator Research Program
  • 2001
    Career Development Award-American Society of Clinical Oncology
  • 2001
    Accelerate Brain Cancer Cure Foundation Award
  • 2002
    UCSF Research Evaluation and Allocation Committee Award
  • 2003
    UC Discovery Grant
  • 2003
    Tobacco-Related Disease Research Program IDEA Award
  • 2004
    National Cancer Institute Research Career Award
  • 2004
    American Cancer Society Award
  • 2005
    UCSF Brain Tumor SPORE Development Award
  • 2006
    G&P Foundation Award
  • 2008
    UCSF Clinical and Translational Sciences Grant
  • 2009
    Scholar in Clinical Research Award, Leukemia & Lymphoma Society
  • 2011
    Sandler Award Program in Breakthrough Biomedical Research
  • 2013
    Translational Research Program Award, Leukemia & Lymphoma Society
    Invited Lectures

Selected Publications

  1. Damato B, Bever GJ, Kim DJ, Afshar AR, Rubenstein JL. An audit of retinal lymphoma treatment at the University of California San Francisco. Eye (Lond). 2019 Jul 29.
    View on PubMed
  2. Ferreri AJM, Holdhoff M, Nayak L, Rubenstein JL. Evolving Treatments for Primary Central Nervous System Lymphoma. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:454-466.
    View on PubMed
  3. Rubenstein JL, Geng H, Vu K, Mannis G, Formaker P, Hwang J, Munster PN, Damato B. Maintenance Lenalidomide in Primary CNS Lymphoma. Ann Oncol. 2019 May 02.
    View on PubMed
  4. Grommes C, Rubenstein JL, DeAngelis LM, Ferreri AJM, Batchelor TT. Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. Neuro Oncol. 2019 Feb 19; 21(3):296-305.
    View on PubMed
  5. Vu K, Mannis G, Hwang J, Geng H, Rubenstein JL. Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma. Br J Haematol. 2019 Jul; 186(1):180-183.
    View on PubMed
  6. Rubenstein JL. Can rituximab unlock the innate potential of checkpoint blockade in the CNS? Leuk Lymphoma. 2019 Feb; 60(2):281-283.
    View on PubMed
  7. Rubenstein JL, Geng H, Fraser EJ, Formaker P, Chen L, Sharma J, Killea P, Choi K, Ventura J, Kurhanewicz J, Lowell C, Hwang J, Treseler P, Sneed PK, Li J, Wang X, Chen N, Gangoiti J, Munster PN, Damato B. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018 07 10; 2(13):1595-1607.
    View on PubMed
  8. Damato BE, Bever GJ, Afshar AR, Rubenstein JL. Insights from a Case of Vitreoretinal Lymphoma. Ocul Oncol Pathol. 2019 Jan; 5(1):13-19.
    View on PubMed
  9. Rubenstein JL. Biology of CNS lymphoma and the potential of novel agents. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):556-564.
    View on PubMed
  10. Bever GJ, Kim DJ, Afshar AR, Rubenstein JL, Damato BE. THERAPEUTIC VITRECTOMY AS AN ADJUNCT TREATMENT TO SYSTEMIC CHEMOTHERAPY FOR INTRAOCULAR LYMPHOMA. Retin Cases Brief Rep. 2017 Nov 23.
    View on PubMed
  11. Gupta NK, Wang CC, Mannis GN, Yu JJ, Rubenstein JL. Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy. Leuk Lymphoma. 2017 11; 58(11):2748-2751.
    View on PubMed
  12. Carnevale J, Rubenstein JL. The Challenge of Primary Central Nervous System Lymphoma. Hematol Oncol Clin North Am. 2016 Dec; 30(6):1293-1316.
    View on PubMed
  13. Gupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DI, Hwang J, Kaplan LD, Luce JA, Volberding P, Treseler PA, Rubenstein JL. Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro Oncol. 2017 01; 19(1):99-108.
    View on PubMed
  14. Kasenda B, Loeffler J, Illerhaus G, Ferreri AJ, Rubenstein J, Batchelor TT. The role of whole brain radiation in primary CNS lymphoma. Blood. 2016 07 07; 128(1):32-6.
    View on PubMed
  15. Korfel A, Chamberlain M, Neuwelt E, Thiel E, Doolittle N, Schlegel U, Dreyling M, Rubenstein J, Fischer L, Björkholm M, Martus P, Weller M, Glantz M. Therapy for Secondary CNS Involvement in Malignant Lymphomas: No Standard Yet! J Clin Oncol. 2016 05 20; 34(15):1829-30.
    View on PubMed
  16. Mabray MC, Cohen BA, Villanueva-Meyer JE, Valles FE, Barajas RF, Rubenstein JL, Cha S. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms. AJR Am J Roentgenol. 2015 Nov; 205(5):1075-85.
    View on PubMed
  17. Shalabi H, Angiolillo A, Vezina G, Rubenstein JL, Pittaluga S, Raffeld M, Marcus L. Prolonged Complete Response in a Pediatric Patient With Primary Peripheral T-Cell Lymphoma of the Central Nervous System. Pediatr Hematol Oncol. 2015; 32(8):529-34.
    View on PubMed
  18. Fraser E, Gruenberg K, Rubenstein JL. New approaches in primary central nervous system lymphoma. Chin Clin Oncol. 2015 Mar; 4(1):11.
    View on PubMed
  19. Okimoto RA, Perry A, Rubenstein JL. 77-year-old woman with a dural-based mass. Marginal zone B-cell lymphoma (MZBCL). Brain Pathol. 2015 Jan; 25(1):111-2.
    View on PubMed
  20. Wang CC, Carnevale J, Rubenstein JL. Progress in central nervous system lymphomas. Br J Haematol. 2014 Aug; 166(3):311-25.
    View on PubMed

Go to UCSF Profiles, powered by CTSI